LYON, France, March 7, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that Harlaching Hospital in Munich, Germany, long-term Ablatherm-HIFU user, is the most active center in the world.

Dr. Christian Chaussy, Head of the Department of Urology at Harlaching Hospital, commented, "We have been treating prostate cancer patients with Ablatherm-HIFU for more than ten years in our Urology Department in Munich with first-hand experience of the different generations of the device. We continue to offer this technology to a growing number of patients. Our patients have experienced favorable treatment outcomes, which have strengthened our commitment and enthusiasm for this technology. We believe HIFU is an effective treatment option for patients with localized prostate cancer."

For years Harlaching Hospital has been on the front line internationally in the therapeutic ultrasound field, sharing its long term leading experience in HIFU. Recently Dr. Chaussy was the main speaker at the Duke Conference in Durham, NC, on Focal Therapy for prostate cancer. His conclusions were: "Prostate cancer is a multi-focal type of cancer currently requiring radical treatment of the entire prostate. HIFU has proven to be an effective and safe treatment option today and exhibits great future potential when a valid diagnosis allowing for the precise identification and targeted treatment of cancer cells becomes available."

In 2007, the number of Ablatherm treatments performed at the center increased by 45% on an annual basis. The center has more than ten years of experience using the technology and leverages its expertise and international recognition, along with scientific publications, patient awareness efforts, and Ablatherm's long-term safety profile to drive adoption within Germany and throughout the globe.

Marc Oczachowski, EDAP's Chief Executive Officer, said, "We are pleased by the continuing adoption of Ablatherm-HIFU across Germany as exemplified by the treatment growth at our leading center in Munich. Under the leadership of Dr. Chaussy, who was the first doctor to treat a patient with extracorporeal shockwave lithotripsy (ESWL) for urinary stone management and is now the leader with his associate Dr. Thuroff in pioneering and using ultrasound in urology, the Harlaching Hospital has been actively and successfully using our Ablatherm device and full product suite for more than ten years ranking as the leading treatment center in 2007. Such enduring support and strong Ablatherm-HIFU activity from a historically leading user clearly confirms that our technology is a consistent, solid and clinically proven therapeutic option for the long-term treatment of prostate cancer."

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com and http://www.hifu-planet.com or http://www.urotoday.com/HIFU.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.

CONTACT:  EDAP TMS SA
          Investor Relations/Legal Affairs
          Blandine Confort
          +33 4 72 15 31 72
          bconfort@edap-tms.com

          The Ruth Group
          Investors:
          Stephanie Carrington
          646-536-7017
          scarrington@theruthgroup.com

          R.J. Pellegrino
          646-536-7009
          rpellegrino@theruthgroup.com